What's the lowest dose of Wegovy and why does it matter?

You've just been told you'll start on 0.25mg, here's what that actually means

Most people searching this question have just received their first Wegovy prescription, or are about to. The dose on the pen says 0.25mg and it sounds very small. That's understandable. There's a persistent belief that a higher number equals faster results, but the 0.25mg starting point is genuinely not about effect, it's about your gut adjusting to a GLP-1 medicine. Semaglutide slows gastric emptying and changes the signals your body uses to regulate hunger; that process can trigger nausea, vomiting or diarrhoea, particularly in the first few weeks. Starting low reduces the severity of those side effects considerably for most people.

The licensed titration schedule, as described in the NHS medicines page for semaglutide, moves through five steps: 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg as the standard maintenance dose. Each step lasts around four weeks. That's roughly five months from first injection to full maintenance dose, a timeline worth knowing before you begin. You can read more about how those steps fit together on the Wegovy doses overview.

One thing worth saying plainly: if the 0.25mg step feels uneventful, that's normal and actually positive. It means the titration is doing its job.

What happens if 0.25mg causes side effects, and when should you be concerned?

Gastrointestinal side effects at the starting dose are common and, for most people, mild. Nausea tends to be the most frequently reported, followed by constipation, loose stools, or a general sense of stomach unsettledness. These usually peak in the first few days after each injection and ease off well before the next one is due. Eating smaller portions, staying well hydrated, and avoiding very fatty or rich meals helps considerably.

There are symptoms that require prompt medical attention rather than waiting it out. Severe or persistent stomach pain, especially pain that radiates through to the back, needs urgent assessment, this can be a sign of pancreatitis, which the MHRA has highlighted as an infrequent but serious risk associated with GLP-1 medicines. Signs of a significant allergic reaction, including facial swelling, difficulty breathing, or a rapid heartbeat, also warrant immediate help. You can report any suspected side effects directly via the MHRA's Yellow Card scheme.

If side effects at 0.25mg are genuinely difficult to manage, talk to your prescriber before moving to the next step. The titration pace is not fixed in stone; a prescriber can extend the time at any given dose. What they should not do (and what no responsible service would do) is skip the starter dose entirely to get to a 'stronger' level faster.

Does the lowest dose of Wegovy produce any weight loss at all?

Technically, yes, but planning around it would give you a misleading picture. In clinical trials, meaningful weight reduction is associated with reaching and staying on the maintenance dose of 2.4mg. The STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks at 2.4mg semaglutide. That figure comes from the full titration period and beyond, not from weeks one to four. Some people do notice reduced appetite even on 0.25mg; others notice nothing at all. Both experiences are reported.

If you're curious about what the evidence actually shows at therapeutic doses, the dedicated page on whether the lowest Wegovy dose works covers that question in more depth. And if you're weighing up whether you can stay at a lower dose long-term rather than titrating up, there's guidance on that question too.

The broader point is that 0.25mg is a starting point on a journey that takes several months to reach its intended destination. Judging the medicine by the first few weeks is like judging a course of antibiotics after a single tablet.

How does this fit into whether Wegovy is right for you?

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, raised cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The prescriber's job is to look at your full picture (not just the number on the scales) before approving any prescription. A full overview of the medicine is on the Wegovy information page.

The NICE technology appraisal for semaglutide (TA875) sets out the criteria under which NHS prescribing is recommended, including the requirement for specialist weight management services and a two-year maximum duration. Private prescribing through a regulated pharmacy follows the licensed criteria in the SmPC rather than the NHS commissioning thresholds, which is why some people access treatment privately when they don't qualify under current NHS phasing. If you have questions about what the lowest dose of Wegovy actually is and how it fits into those criteria, that page walks through the detail clearly.

On the cost side of things, private Wegovy treatment is priced per pen and varies between providers; the weight-loss treatment overview covers what to look for when comparing services. If you're ready to find out whether Wegovy is a clinically appropriate option for you, a prescriber at nume can review your consultation the same day it arrives, and our page on what's the lowest dose of Wegovy is a helpful starting point if you want to understand exactly where treatment begins.